A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic
A phase 3 trial of Zimberelimab run by Guangzhou Gloria Biosciences Co., Ltd. in cervical cancer, now recruiting.
Overview
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT05798819 by Guangzhou Gloria Biosciences Co., Ltd., with 424 participants planned, started 2023-04-20. Conditions listed: Persistent, Recurrent, or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Phase
Phase 3
Sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Registry
Enrolled
424